MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

近日，厦门大学生命科学学院刘亮教授团队在《Nucleic Acids Research》期刊上在线发表了题为“DNA target binding-induced pre-crRNA processing in type II and V ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing.

Genome editing with CRISPR-Cas is often associated with the induction of mutations. However, a team of researchers from the Swiss University of Lausanne now shows that it can also be used to repair ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

The global gene therapy market size was valued at USD 6.30 billion in 2024 and is projected to reach from USD 7.47 billion in ...

Sep. 23, 2024 — CRISPR-Cas is used broadly in research and medicine to edit, insert, delete or regulate genes in organisms. TnpB is an ancestor of this well-known 'gene scissor' but is much ...

编者按：CRISPR/Cas系统是一种强大的基因编辑工具，其在临床中的应用已经展现出广泛的可能性和潜力，尤其是在基因治疗和 ...

In gene and cell therapy, RNP-mediated CRISPR gene editing is quickly emerging as the new norm. For many gene editing firms, GenScript has created hundreds of Cas9, Cas12a, Cas13a, MAD7 ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...